Next Article in Journal
GBT440 Inhibits Sickling of Sickle Cell Trait Blood under In Vitro Conditions Mimicking Strenuous Exercise
Previous Article in Journal
Refractory Ascites with Liver Fibrosis Developed in Late Phase Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 8
Issue 3
10.4081/hr.2016.6593
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Brentuximab Vedotin Therapy for Cutaneous Lesions in T-prolymphocytic Leukemia: A Case Report

by
Jordan Senchak
1,* and
Peter Pickens
2
1
Drexel University College of Medicine, Philadelphia, 2510 Maryland Road, Willowood Building Suite 175, Willow Grove, PA 19090, USA
2
Department of Hematology/Oncology, Abington Memorial Hospital, Abington, PA, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2016, 8(3), 6593; https://doi.org/10.4081/hr.2016.6593
Submission received: 10 May 2016 / Revised: 11 June 2016 / Accepted: 30 August 2016 / Published: 28 September 2016

Abstract

We present an 88-year-old male with simultaneous T-cell prolymphocytic leukemia and stable smoldering myeloma with excellent initial response to three months of alemtuzumab. The patient relapsed at twelve months with severe cutaneous disease. Biopsy of a representative plaque demonstrated CD30 positivity in rare malignant lymphocytes. The patient demonstrated no response to reintroduction with a full course of alemtuzumab. He was therefore treated with brentuximab vedotin, resulting in partial remission of skin involvement that persisted for three months.
Keywords: T-prolymphocytic leukemia; brentuximab vedotin; alemtuzumab T-prolymphocytic leukemia; brentuximab vedotin; alemtuzumab

Share and Cite

MDPI and ACS Style

Senchak, J.; Pickens, P. Brentuximab Vedotin Therapy for Cutaneous Lesions in T-prolymphocytic Leukemia: A Case Report. Hematol. Rep. 2016, 8, 6593. https://doi.org/10.4081/hr.2016.6593

AMA Style

Senchak J, Pickens P. Brentuximab Vedotin Therapy for Cutaneous Lesions in T-prolymphocytic Leukemia: A Case Report. Hematology Reports. 2016; 8(3):6593. https://doi.org/10.4081/hr.2016.6593

Chicago/Turabian Style

Senchak, Jordan, and Peter Pickens. 2016. "Brentuximab Vedotin Therapy for Cutaneous Lesions in T-prolymphocytic Leukemia: A Case Report" Hematology Reports 8, no. 3: 6593. https://doi.org/10.4081/hr.2016.6593

APA Style

Senchak, J., & Pickens, P. (2016). Brentuximab Vedotin Therapy for Cutaneous Lesions in T-prolymphocytic Leukemia: A Case Report. Hematology Reports, 8(3), 6593. https://doi.org/10.4081/hr.2016.6593

Article Metrics

Back to TopTop